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In this review, we identify opportunities for drug discovery in the treatment of
COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and
pharmacologists can mitigate against the global pandemic. We assess the scope for
targeting key host and viral targets in the mid-term, by first screening these targets
against drugs already licensed, an agenda for drug repurposing, which should allow
rapid translation to clinical trials. A simultaneous, multi-pronged approach using con-
ventional drug discovery methods aimed at discovering novel chemical and biological
means of targeting a short list of host and viral entities which should extend the arse-
nal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper
pool of drug choices for future-proofing against acquired drug resistance. Second,
there will be further viral threats, which will inevitably evade existing vaccines. This
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will require a coherent therapeutic strategy which pharmacology and pharmacologists
are best placed to provide.
1 | INTRODUCTION
PubMed has already accumulated a vast repository of information on
SARS-CoV-2/COVID-19, which increases on a daily basis
(on 2020-03-23, there were 1,369 hits for COVID-19; this number
more than doubled in the space of 2 weeks, so that by 2020-04-06
there were 2,780 hits in PubMed for COVID-19). Clearly, there is a
need to summarize this information critically and prioritize the ele-
ments, which are constructive and useful for each individual sector.
This review suggests priorities for how drug discovery and develop-
ment might be rationally focussed for the rapid identification and suc-
cessful translation of therapeutic agents to treat COVID-19.
Given the urgency of the current situation, clearly, initial drug dis-
covery should focus on repurposing licensed drugs, as dosage and
safety information are largely to hand. Unfortunately, there is contro-
versy over proof of efficacy for essentially all the potential repurposed
agents for which preliminary and, in many cases, non-peer reviewed
data have surfaced. Some of this controversy is addressed below, but
efforts are underway from both WHO and NIH to coordinate larger,
higher powered and better controlled studies in an attempt to demon-
strate efficacy unequivocally. As a “second wave,” de novo discovery
focussing on novel agents may allow future refinement and capacity
to treat patients who are unable to be treated by, or are unresponsive
to, the repurposed agents, but it would be very unlikely to have these
new drugs available to treat the current crisis.
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) is an
open-access database, developed by the International Union of Basic
and Clinical Pharmacology (IUPHAR) and the British Pharmacological
Society (BPS). It provides expert-curated descriptions of almost 3,000
human proteins and over 10,000 ligands, including more than 1,400
approved drugs. Management of the resource is the responsibility of
the Nomenclature and Standards Committee of IUPHAR (NC-
IUPHAR), which acts as the scientific advisory and editorial board.
The committee has an international network of over 700 expert vol-
unteers organized into 60 subcommittees dealing with individual
target families. The database is notably enhanced through the contin-
ued linking of relevant pharmacology with key immunological data
types as part of the IUPHAR Guide to IMMUNOPHARMACOLOGY
(supported by the Wellcome Trust) and by a major new extension, the
IUPHAR/MMV Guide to Malaria PHARMACOLOGY (in partnership
with the Medicines for Malaria Venture). The GtoPdb team centred at
the University of Edinburgh have constructed a resource (Coronavirus
Information Portal), which provides a precis of the current under-
standing about the virus and potential associated drug targets and
drugs. As with the other databases, the emphasis of the curation pro-
cess is on stringent provenancing of the information provided,
although inevitably the current situation limits the capacity for trian-
gulation of data.
2 | THE VIRAL CYCLE AND VIRALLY
ENCODED POTENTIAL DRUG TARGETS
For general reviews of the coronaviruses, see Masters (2006); Fehr
and Perlman (2015); de Wit, van Doremalen, Falzarano, and
Munster (2016); Zumla, Chan, Azhar, Hui, and Yuen (2016); Cui, Li,
and Shi (2019); Desforges et al. (2019); and Song et al. (2019). SARS-
CoV-2 is a betacoronavirus, a lipid-enveloped, single-stranded and
positive sense RNA virus. Other human coronaviruses include
alphacoronaviruses, such as human coronavirus-229E (HCoV-229E),
and betacoronaviruses, such as SARS-CoV and MERS-CoV (responsi-
ble for the Middle East respiratory syndrome) (for review, see Zumla
et al., 2016; Corman, Muth, Niemeyer, & Drosten, 2018; Pillaiyar,
Meenakshisundaram, & Manickam, 2020). More than 200 viral types
have been associated with the common cold, of which 50% of
infections are rhinovirus, but also include respiratory syncytial virus,
influenza and coronaviruses, particularly HCoV-229E. Although
HCoV-229E is regarded as “relatively benign” since monocytes are
much more resistant to infection, it does rapidly kill dendritic cells
(Mesel-Lemoine et al., 2012).
Classically, the viral life cycle can be divided into six elements:-
cell attachment, cell entry, viral uncoating, nucleotide replication, viral
assembly and release (see Figure 1). Positive-stranded RNA viruses
replicate in the cytoplasm of infected cells, in close contact with intra-
cellular membranes. This organization allows a concentration of viral
and host factors to enable virus production and to evade innate
immune responses (reviewed by Yager & Konan, 2019).
The SARS-CoV-2 coronavirus 30-kb genome has 15 open
reading frames (ORFs), two of which encode viral polyproteins that
generate 16 non-structural proteins (see below) (Wu et al., 2020).
Historically, therapeutic benefit has been gained through exploita-
tion of the differences between viral and host proteins that
subserve superficially similar functions (proteases and nucleotide
polymerases, for example). The rapidity with which structural
elements of the SARS-CoV-2 proteome have been identified
provides hope that drug discovery approaches will soon provide
agents to target the virus selectively, with minimal impact on the
host. Based on the evidence from orthologous proteins from other
betacoronaviruses and the information currently available on SARS-
CoV-2 (some of it not yet from peer-reviewed sources), we propose
here the priority targets for pharmacological investigation. That
should not be taken to mean that research should be limited to
these targets, since there are undoubtedly a number of functions of
the viral proteins still to be ascertained. It would be remiss not to
conduct a thorough examination of all the viral proteome, both in
isolation and in combination. The strategies we learn from investiga-
tion of the host:viral interaction from SARS-CoV-2 will stand us in
good stead for future viral threats.
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2.1 | Cellular attachment and entry: replication,
assembly and release
Coronavirus binds to cell surface proteins on target cells and, follow-
ing proteinase priming of spike proteins on the virus surface, the virus
is internalized into endosomal fractions that are subsequently acidified
or accumulates through a non-endosomal route (Fehr &
Perlman, 2015) (Figure 1). The endosomal route appears to involve
clathrin (Inoue et al., 2007), but there are contradictory reports of the
importance of the intracellular C-terminus of ACE2 in this mechanism
(Haga et al., 2008; Inoue et al., 2007). A fusion domain permits inser-
tion of a key protein (the spike glycoprotein of the virus, S, see below),
which then allows mixing of the viral and cellular membranes and sub-
sequent release of the coronaviral genome into the cytoplasm.
Following entry into the host cell cytoplasm and viral uncoating,
the replicase gene of the viral RNA is translated. The genome of cor-
onaviruses consists of a single, continuous and linear ssRNA, capped
at the 50 end and with a 30-polyA tail (Fehr & Perlman, 2015). Trans-
lation occurs from ORF1a and 1b at the 50 terminus, with a ribo-
somal frameshifting mechanism allowing the overlap between ORF1a
and ORF1b to generate the two polyproteins pp1a and pp1ab (Fehr
& Perlman, 2015; Perlman & Netland, 2009; Snijder et al., 2003;
Thiel et al., 2003). In SARS-CoV-2, the polyproteins are long, 4,405
and 7,096 amino acids respectively. Encoded within the polyproteins
F IGURE 1 The SARS-CoV-2 life cycle. The novel virus uses ACE2 to attach to target cells, including epithelial and endothelial cells,
particularly in the lungs. SARS-CoV-2 requires the camostat-sensitive serine proteinase TMPRSS2 to prime the spike protein for fusion and
internalization. Thereafter, host cellular processes are exploited for viral replication and release from the cell. ACE2 is also expressed in high levels
in the GI tract, where it is associated with B0AT1/SLC6A19 that actively transports neutral amino acids across the apical membrane of epithelial
cells. The serine proteinase ADAM17, present on cell surfaces, cleaves ACE2 to release an ectodomain of ACE2, including the active site, into the
circulation. This circulating form of ACE2 may also bind SARS-CoV-2, but this complex is predicted not to internalize and therefore could be
exploited as a beneficial viral decoy. Recombinant ACE2 (GSK2586881) has been tested in Phase 2 clinical trials for the potential treatment of
acute respiratory distress syndrome, but it is not yet established if the compound will reduce viral load by acting as a decoy
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of betacoronaviruses are two proteinases, papain-like proteinase
(PLpro) and chymotrypsin-like proteinase (3CLpro). In SARS-CoV,
PLpro, derived from the polyproteins, has three endoproteinase tar-
get sites, which release nsp1–3 (Thiel et al., 2003). 3CLpro has
11 cleavage sites to release the remaining non-structural proteins. In
the coronavirus family, these proteinases process the polyproteins to
generate 16 functional non-structural proteins identified as nsp1–16
(Anand, Ziebuhr, Wadhwani, Mesters, & Hilgenfeld, 2003; Cui
et al., 2019; Kindler, Thiel, & Weber, 2016; Thiel et al., 2003;
Ziebuhr et al., 2007).
Downstream of the ORF1a and 1b are genes encoding four
structural proteins (spike, envelope, membrane and nucleocapsid)
(Figure 2) and a short series (described as at least 13 in total,
Srinivasan et al., 2020) of other proteins (see below). Once
sufficient protein and RNA accumulate, coronavirus assembly takes
place, centred on the structural proteins. The release of coronavi-
rus particles involves the secretory pathway of the endoplasmic
reticulum and Golgi apparatus and vesicular exocytosis (for review,
see de Haan & Rottier, 2005; Fehr & Perlman, 2015) and it is
likely, but as yet unconfirmed, that SARS-CoV-2 also adopts
this mechanism.
To date, there is more evidence about the molecular detail
involved in (and the possibilities to modify) viral recognition, entry and
replication compared to uncoating, assembly and release, hence the
attention paid here to the former three mechanisms.
3 | TARGETING VIRUS RECOGNITION AND
CELLULAR ENTRY
3.1 | The cell-surface anchor - ACE2
Among the coronaviruses, the spike protein interacts with proteinases
to anchor on host cell surfaces. The cell-surface anchoring point for
the alphacoronavirus HCoV-229E is aminopeptidase N (also known
as CD13, Yeager et al., 1992). For the betacoronavirus MERS-CoV,
dipeptidylpeptidase 4 (also known as CD26, Raj et al., 2013) is an
anchor. Analysis of the co-crystal structure suggested that the SARS
spike protein binds to the active site of ACE2 (Li, Li, Farzan, &
Harrison, 2005). Binding of SARS-CoV spike to ACE2 seems to require
cholesterol-rich rafts in the host cells (Glende et al., 2008). Recent evi-
dence points to the spike protein of SARS-CoV-2 also binding to
ACE2. Both SARS-CoV (Li et al., 2003) and SARS-CoV-2 (Hoffmann
et al., 2020; Letko, Marzi, & Munster, 2020) have been described to
require ACE2 to enter cells (Figure 1). A particular domain of the spike
protein of SARS-CoV-2, a so-called receptor-binding domain (RBD),
F IGURE 2 A cartoon of the virus structure, identifying the four structural proteins and the viral genome
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has been shown to facilitate binding to ACE2 (Hoffmann et al., 2020).
The ACE2 peptidase active site is located remotely from the cell mem-
brane (Li et al., 2005; Wrapp et al., 2020; Yan et al., 2020), into which
the spike protein binds. The receptor-binding domain of the spike pro-
tein is located in the S1 ectodomain, approximately a third of the way
along the protein. ACE2 is a carboxypeptidase, which means it
removes the terminal amino acid from oligopeptides, and so it seems
unlikely that the spike protein is a substrate for ACE2.
In SARS-CoV-infected mouse lung, ACE2 protein expression was
down-regulated compared to uninfected mice (Kuba et al., 2005). Fol-
lowing SARS-CoV spike protein administration to mice, angiotensin II
was increased in the lungs (Kuba et al., 2005). These observations led
to the suggestion that this was the molecular mechanism for the fre-
quent development of acute respiratory distress syndrome (ARDS)
during SARS-CoV infections (Imai et al., 2005; Kuba et al., 2005).
ACE2 has been reported to be released from plasma membranes
by proteolysis, thought to be through the action of TNFα convertase
(ADAM17, a disintegrin and metalloproteinase domain containing pro-
tein 17, Lambert et al., 2005) (Figure 1). The activity of ADAM17 can
be increased by GPCR activation, including the AT1 angiotensin recep-
tor (Schafer, Marg, Gschwind, & Ullrich, 2004). ACE2 and ACE activi-
ties can be measured in human plasma (Herath et al., 2007; Lew
et al., 2008; Ocaranza et al., 2006). Human plasma ACE2 activity is
reported to be 'masked' by the presence of endogenous inhibitors
(Lew et al., 2008), which do not yet appear to have been precisely
defined. Blood ACE2 activity can be altered in pathology; for example,
serum ACE2 was found to be decreased in patients following acute
ischaemic stroke (Bennion et al., 2016).
The expression of ACE2 mRNA and enzyme activity in cardiac tis-
sues were increased following repeated p.o. administration of the AT1
receptor antagonist losartan, while p.o. administration of an ACE
inhibitor lisinopril only increased cardiac mRNA expression, but not
enzyme activity (Ferrario et al., 2005).
Studies using disruption of the ace2 gene in mice indicated an
increase in circulating angiotensin II levels and a severe cardiac con-
tractility defect, which could be 'rescued' with simultaneous genetic
disruption of ACE (Crackower et al., 2002). An early investigation of
ACE2 polymorphisms in man failed to show an association with hyper-
tension (Benjafield, Wang, & Morris, 2004). A study of SARS victims
and ACE2 polymorphisms failed to find a correlation with patient out-
comes (Chiu et al., 2004).
3.2 | The coronaviral spike protein
The spike protein is the largest viral structural protein (1,200–1,400
amino acids) and is heavily glycosylated, forming extended trimeric
structures providing the characteristic “crown” feature of cor-
onaviruses (Belouzard, Millet, Licitra, & Whittaker, 2012) (see
Figure 2). The ectodomain is divided into the S1 domain responsible
for binding to ACE2, whereas the S2 domain is responsible for the
fusion machinery. Following binding of the S1 domain to ACE2, a
deformation of the pre-fusion trimer results (Wrapp et al., 2020).
Surface plasmon resonance of the binding of human ACE2 to the
immobilized SARS-CoV-2 indicated an affinity (KD value) of 15 nM, an
order of magnitude larger than SARS-CoV binding to ACE2 (Wrapp
et al., 2020). Using a related label-free technique, biolayer interferom-
etry, affinities of 5 and 1.2 nM for binding of SARS-CoV and SARS-
CoV-2 spike protein, respectively, to human ACE2 has been reported
(Walls et al., 2020).
Although a proteolytic cleavage site at the S1/S2 boundary of the
SARS-CoV spike protein is best characterized, a second site upstream
of the fusion peptide in the S2 domain, called S20 , has also been
described (Belouzard, Chu, & Whittaker, 2009). This raises the possi-
bility that multiple other proteases might be targeted to influence
coronavirus activation (Millet & Whittaker, 2015). A key difference
between the spike proteins in SARS-CoV and SARS-CoV-2 is the
presence in the latter of a site at the S1/S2 boundary predicted to be
sensitive to the proteinase furin, and which may be targeted during
viral assembly and maturation (Walls et al., 2020).
The SARS-CoV S2 domain has a pair of α-helices, which may par-
ticipate in coiled:coil structures during membrane fusion (Petit
et al., 2005). The host complex of ZDHHC9 (Link to UniProt) with
GOLGA7 (Link to UniProt), a palmitoyltransferase, which modifies the
low MW G proteins NRAS and HRAS (Swarthout et al., 2005), also
palmitoylates the cysteine-rich S2 endodomain of the SARS-CoV to
facilitate membrane fusion (Petit et al., 2007).
Very recently, in a comparison of the S2 domains of SARS-
CoV and SARS-Cov-2, an enhanced capacity of the novel virus' S2
domain for membrane fusion was observed and suggested to
result from eight differing amino acids (Xia et al., 2020). Using a
series of oligopeptides conjugated to lipid entities, high affinity
(IC50 values in the nanomolar range) inhibitors of cell fusion
were identified.
3.3 | Interfering with the ACE2:spike protein
interaction
Given that the spike protein binds to the active site of ACE2
(Li et al., 2005), in theory, any alteration in the availability of the active
site should influence the binding of the spike protein and, hence,
interfere with SARS-CoV-2 infection. One option would be to provide
an excess of an endogenous peptide substrate, or more convention-
ally to apply a selective enzyme inhibitor.
3.3.1 | Endogenous substrates of ACE2
ACE2, discovered in 2000 (Donoghue et al., 2000), shares 40%
sequence similarity to ACE within the N-terminal domain and is a type
I transmembrane metallopeptidase. Unlike ACE, it functions as a zinc
carboxypeptidase to cleave single C-terminal amino acids from pep-
tides, particularly hydrolysing Pro-Phe residues in angiotensin-(1–8) to
angiotensin-(1–7), [Pyr1]-apelin 13 to [Pyr1]-apelin-(1–12) and [des-
Arg9]-bradykinin to bradykinin-(1–8) with high efficiency. It may also
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cleave other peptides less effectively (Vickers et al., 2002), shown
below:
Angiotensin I ⇨ angiotensin-(1–9) + Leu
Angiotensin II ⇨ angiotensin-(1–7) + Phe
Apelin-(1–13) ⇨ QRPRLSHKGPMP + Phe
Apelin-(1–36) ⇨ …. QRPRLSHKGPMP + Phe
[Des-Arg9]-Bradykinin ⇨ RPPGFSP + Phe
Dynorphin A-(1–13) ⇨ YGGFLRRIRPKL + Lys
115 other peptides were not hydrolysed by ACE2 including
adrenocorticotrophic hormone, calcitonin, cholecystokinin,
met-enkephalin, glucagon, glucagon-like peptide-1, melanin-
concentrating hormone, pituitary adenylyl cyclase-activating polypep-
tide, somatastatin-14, urocortin or vasoactive polypeptide (Vickers
et al., 2002).
In humans, levels of mRNA encoding ACE2, together with immu-
noreactive peptide, are highest in the gastrointestinal tract, followed
by heart, kidney, testes and gall bladder, and other tissues (Uhlen
et al., 2015). Within organs, ACE2 immunoreactivity was predomi-
nantly localized to epithelial (for example, in the lungs) and endothelial
cells from all vascular beds examined (Yang et al., 2017). Importantly,
the ACE2 antisera used in this study for immunocytochemistry was
the same as that employed in the study described in Section 3.3.3
(Hoffmann et al., 2020), to block entry of the virus in cell culture. The
epitope of this antisera would be a rational starting point for the
development of selective therapeutic antibodies.
The presence of ACE2 on airway epithelial cells is consistent with
the isolation of SARS-CoV-2 from broncho-alveolar lavage of patients
with COVID-19 and the infection of cultured airway epithelial cells
(Zhu et al., 2020). In humans, levels of ACE2 immunoreactivity tend to
be low. However, in addition to being up-regulated by ACE inhibitors
and angiotensin receptor antagonists (see above), ACE2 expression
has been reported to be increased in human cardiovascular disease,
for example, in the cardiomyopathic heart (Zisman et al., 2003). Since
ACE2 is critical for viral entry, it may be one explanation for the high
incidence of co-morbidity of COVID-19 patients with cardiovascular
disease.
3.3.2 | Manipulation of ACE2 activity by synthetic
agents
Assays employing fluorogenic surrogate substrates to screen for inhib-
itors of ACE2 activity are well-established, for example, using
methoxycoumarin-RPPGFSAFK (Dnp)-OH (Bennion et al., 2016;
Ocaranza et al., 2006) or methoxycoumarin-APK (Dnp)OH (Herath
et al., 2007; Lew et al., 2008; Mores et al., 2008). Detailed protocols
for the use of methoxycoumarin-APK (Dnp)OH have been described
for FRET-based high throughput screening (Sriramula, Pedersen, Xia,
& Lazartigues, 2017; Xiao & Burns, 2017).
This style of assay identified that ACE2 was not inhibited in the
presence of 10μM lisinopril, enalaprilat or captopril, inhibitors of ACE
(Tipnis et al., 2000). There are no licensed drugs described to inhibit
ACE2 activity. However, DX600 is a peptide-based ACE2 inhibitor
(Huang et al., 2003), whileMLN4760 and compound 28 are described
as sub-nanomolar potency ACE2 inhibitors (Mores et al., 2008).
There is evidence for allosteric regulation of ACE2 activity, in that
a xanthenone derivative (XNT) was observed to enhance ACE2, but
not ACE, activity in vitro with a potency of 20 μM (Hernandez Prada
et al., 2008). An in silico study later identified a binding site in an allo-
steric hinge region of ACE2, distinct from the proteinase active site,
against which 1,217 FDA-approved drugs were screened (Kulemina &
Ostrov, 2011). A subsequent kinetic assay with the recombinant
enzyme and a fluorigenic substrate identified labetalol and
diminazene as agents able to double the maximal velocity of ACE2
enzyme activity.
Whether any of these compounds alter the binding of the spike
protein from either SARS-CoV or SARS-CoV-2 or viral infection in
general does not appear to have been examined yet.
A speculative area that should be explored further is the concept
of enhancing the activity of the serine proteinase ADAM17 to
increase cleavage and release of ACE2 from the membrane. Peptides
such as angiotensin II are reported in animal models to cause release
(“shedding”) following binding to AT1 receptors (Xu et al., 2017).
Although angiotensin II is licensed by the Federal Drug Administration
to treat sepsis (known as Giapreza, Davenport, Scully, de Graaf,
Brown, & Maguire, 2020), it would be inadvisable as a treatment for
COVID-19 given the detrimental action of angiotensin II on the lungs.
In contrast, the investigational agent [Pyr1]-apelin-13 is currently used
in clinical studies (Davenport et al., 2020) and may also interact with
its cognate receptor to down-regulate membrane-expressed ACE2.
This peptide also has beneficial effects on the heart, including an
increase in cardiac output (Japp et al., 2010).
3.3.3 | Using biopharmaceutical/antibody
approaches to target ACE2:spike interactions
An alternative approach to the small molecule manipulation of the
ACE2 enzyme would be to target the spike or ACE2 proteins with
selective antibodies. Antibodies directed against ACE2 led to a reduc-
tion in SARS-CoV-2 virus entry into target cells (Hoffmann
et al., 2020), although this is likely to be some distance away from a
therapeutic application.
A truncated version of human recombinant ACE2, lacking the
transmembrane domain, mitigated against SARS-CoV infection of cells
(Li et al., 2003) and has been used in animal models to reduce symp-
toms of severe acute lung failure (Imai et al., 2005), diabetic nephropa-
thy (Oudit et al., 2010), and cardiac hypertrophy and fibrosis (Zhong
et al., 2010). Treating SARS-CoV-2 victims with a soluble form of
ACE2 (Batlle, Wysocki, & Satchell, 2020) or a fusion protein of the
spike-binding portion of ACE2 combined with the Fc portion of
human IgG (Lei et al., 2020) has been suggested.
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Apeiron Biologics has approval to conduct a Phase II clinical
trial of APN01 (human recombinant ACE2) for the treatment of
COVID-19 in three European countries (Austria, Germany and Den-
mark) (NCT04335136). This recombinant version of ACE2 was origi-
nally licensed to GlaxoSmithKline and previously tested as
GSK2586881 in a Phase 2 multicentre trial (NCT01597635) in
patients with lung injury or acute respiratory distress syndrome,
both features of SARS and MERS (and now COVID-19). The study
tested the hypothesis that cleavage of angiotensin II (which causes
lung injury—vasoconstriction, inflammation, fibrosis, vascular leak
and sodium absorption) to angiotensin-(1–7) would have counter
regulatory beneficial action and reduce long term injury.
GSK2586881 was well-tolerated in patients with acute respiratory
distress syndrome and the rapid modulation of peptides of the
renin-angiotensin system demonstrated target engagement, in that
levels of angiotensin II decreased rapidly, whereas angiotensin-(1–7)
levels increased and remained elevated for 48 h, although the study
was not powered to detect changes in acute physiology or clinical
outcomes (Khan et al., 2017).
Sera from convalescent SARS-CoV patients prevented the cell
entry of SARS-CoV-2 (Hoffmann et al., 2020) and this approach has
been used with some success in the SARS, MERS and COVID-19 out-
breaks (for review, see Bloch et al., 2020). The difficulty in identifying
the precise molecular mechanism/s of convalescent sera action and
issues with collection, standardization and scaling-up will be a chal-
lenge (Bloch et al., 2020).
A bacterial equivalent of ACE2 (based on 3D structure rather than
primary sequence) termed B38-CAP has been described, which is
reported to reduce hypertension and limit cardiac dysfunction in an
animal model (Minato et al., 2020). Whether this agent might provide
a decoy anchor to “chelate” viral particles prior to cell entry has not
been investigated.
In a preliminary (as yet, not peer reviewed) study, a conforma-
tional change in the S1 receptor-binding domain of the SARS-CoV-2
spike protein in the presence of heparin was noted (Mycroft-West
et al., 2020). Cell-surface heparan sulphate glycosaminoglycans have
previously been suggested to be a lactoferrin-sensitive alternative
attachment point for the SARS-CoV virus (Lang et al., 2011). These
observations suggest further routes for pharmacological targeting of
viral infection and propagation.
3.4 | The cell-surface priming mechanism -
TMPRSS2
TMPRSS2 is a single transmembrane domain protein with an extracel-
lular serine protease domain, which appears to cleave substrates pref-
erentially at basic residues (arg/lys), with a calcium-binding LDL
receptor class A domain (Paoloni-Giacobino, Chen, Peitsch, Rossier, &
Antonarakis, 1997). The TMPRSS2 gene encodes a cell-surface pro-
teinase (transmembrane serine protease 2, TMPRSS2) and is located
at chromosomal locus 21q22.3 in close proximity to ERG, a gene
encoding an ETS transcription factor (Link to UniProt, Paoloni-
Giacobino et al., 1997) (ERG fusion with EWS leads to Ewing's sar-
coma). Fusion of the TMPRSS2 and ERG (or the related ETV1) genes
has been reported to occur in the majority of prostate cancers and is
suggested to lead to an androgen-dependent amplification of ETS-
regulated genes (Tomlins et al., 2005). TMPRSS2 expression is
androgen-regulated (Chen et al., 2019; Lin et al., 1999). It is expressed
highly in prostate cancer (Lin et al., 1999; Lucas et al., 2008) (for
review, see Tanabe & List, 2017) and loss of TMPRSS2 in the prostate
is associated with reduced metastatic potential (Lucas et al., 2014). In
aggressive versions of prostate cancer, TMPRSS2 undergoes autocat-
alytic proteolysis at Arg255-Ile256 (Afar et al., 2001), where the two
chains may remain in combination due to interchain disulphide bridges
(Chen et al., 2010) or the catalytic moiety may be secreted (Chen
et al., 2010). In LNCaP human prostate cancer cells, the PPARα
(NR1C1) agonist fenofibrate was able to mitigate against the andro-
gen receptor agonist-evoked increase in TMPRSS2 expression (Zhao
et al., 2013).
Following binding of the S protein to ACE2, TMPRSS2
“primes” the spike protein to facilitate entry of the virus into the
target cell (Hoffmann et al., 2020; Matsuyama et al., 2020). Patho-
genesis of two strains of influenza virus has been reported to be
markedly diminished by gene disruption of tmprss2 in mice
(Hatesuer et al., 2013; Tarnow et al., 2014), inferring that targeting
this enzyme may have antiviral potential.
3.4.1 | Interfering with the TMPRSS2:spike protein
interaction
Using immunohistochemical analysis (Bertram et al., 2012) and, very
recently, using single nuclei and single-cell RNA sequencing
(Lukassen et al., 2020), of lung samples from otherwise healthy sub-
jects, ACE2 and TMPRSS2 were shown to be co-expressed in
human bronchial epithelial cells, which could be a nexus for primary
infection. A similar approach identified co-expression of ACE2 and
TMPRSS2 in nasal goblet cells, lung type II pneumocytes and small
intestine absorptive epithelia (Ziegler et al., 2020). In the same study,
human primary nasal epithelial cells showed an up-regulation in
ACE2 expression following 12h incubation with IFN-α2 and IFN-γ,
which suggests the potential for a feed-forward mechanism
whereby the virus interacts preferentially with “activated” cells to
suppress the innate immune response (see below) (Ziegler
et al., 2020).
By analogy with the previous consideration of ACE2 (above),
alternatives to manipulate TMPRSS2 activity would be to provide
endogenous substrates or synthetic inhibitors. However, the potential
to make use of endogenous substrates seems limited. Thus, although
TMPRSS2 has been described to hydrolyse and activate the cell-
surface GPCR proteinase-activated receptor 2 (Wilson et al., 2005),
mice lacking tmprss2 failed to display an overt phenotype (Kim,
Heinlein, Hackman, & Nelson, 2006).
As with ACE2, there are no reports of licensed drugs which
inhibit TMPRSS2 activity. Cbz-GGR-aminomethylcoumarin has been
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described as a surrogate fluorogenic substrate suitable for high-
throughput screening (Paszti-Gere et al., 2016), although it is also a
substrate for other proteinases, such as chymotrypsin. I432, a
3-amidinophenylalanine, has been described as a high affinity selec-
tive inhibitor (compound 92, Ki of 0.9 nM) of TMPRSS2 (Meyer
et al., 2013). In IPEC-J2 pig jejunal epithelial cells, 10- to 50-μM I432
reduced TMPRSS2-derived product in cell media (Paszti-Gere
et al., 2016).
In an investigation of SARS-CoV entry into HeLa cells
expressing recombinant ACE2 and TMPRSS2, a number of serine
proteinase inhibitors (benzamidine, aprotinin, gabexate, tosyl lysyl
chloromethyl ketone and camostat) were tested (mostly) at 10 μM
for 30 min before exposure to pseudotyped viruses. Only camostat
was effective at reducing viral entry (Kawase, Shirato, van der Hoek,
Taguchi, & Matsuyama, 2012) and further experiment suggested
that 1 μM camostat was also effective, but only when TMPRSS2
was expressed. At 10 and 50 μM, camostat inhibited cell entry of
the SARS-CoV and SARS-CoV-2 spike protein (Hoffmann
et al., 2020). A direct inhibition of TMPRSS2 activity appears not to
have been reported for camostat.
3.5 | Potential ancillary proteins for virus
entry - B0AT1/SLC6A19 and B0AT3/SLC6A18
The SLC6 family of transporters includes the well-characterized
NET, SERT and DAT monoamine transporters, as well as the less
well-exploited neutral amino acid transporter subfamily. B0AT1/
SLC6A19 and B0AT3/SLC6A18 allow sodium- and chloride-
dependent accumulation of neutral, aliphatic amino acids at the api-
cal membranes of epithelial cells in the small intestine (B0AT1/
SLC6A19) and kidney (B0AT1/SLC6A19 and B0AT3/SLC6A18) (for
review, see Broer & Gether, 2012). B0AT3/SLC6A18 is also highly
expressed in the GI tract and gall bladder (Protein Atlas). The cell-
surface expression of these neutral amino acid transporters is
dependent on co-expression of ACE2 (Fairweather, Broer, O'Mara,
& Broer, 2012; Kowalczuk et al., 2008), aminopeptidase N
(Fairweather et al., 2012) or collectrin (an adaptor protein, which
has high homology to the transmembrane region of ACE2, Camargo
et al., 2009, Link to UniProt), in an apparently tissue-dependent
manner (Kuba, Imai, Ohto-Nakanishi, & Penninger, 2010). A recent
cryo-EM structure suggested that ACE2 and B0AT1/SLC6A19 form
a heterodimer, which pairs up through interfaces between the two
ACE2 partners (Figure 1), with the receptor-binding domain of
SARS-CoV-2 spike protein binding to the peptidase active site of
ACE2 (Yan et al., 2020) suggesting that B0AT1/SLC6A19 may facili-
tate entry of the novel coronavirus. In the small intestine, absorptive
epithelial cells were identified to co-express mRNAs encoding for
ACE2 and TMPRSS2 (Ziegler et al., 2020). Although it is not yet
tested, it would be attractive to speculate that the co-localized
expression of these targets may play a role in the faecal:oral trans-
mission of coronavirus (Yeo, Kaushal, & Yeo, 2020).
3.5.1 | Interfering with the neutral amino acid
transporters
Assays for B0AT1/SLC6A19 and B0AT3/SLC6A18 tend to be tradi-
tional accumulation of amino acids labelled with ionizing or stable
isotopes. Recently, a primary screen using a membrane potential-
sensitive fluorescence-based assay was used and followed up with a
stable isotope accumulation assay to identify a novel inhibitor,
cinromide, which exhibited modest potency (0.3–0.4 μM) for
inhibiting B0AT1/SLC6A19 in cell-based assays (Danthi et al., 2019).
4 | TARGETING VIRAL UNCOATING AND
REPLICATION
4.1 | Viral uncoating
Once inside the cell, the endosomal cysteine proteases cathepsin B
and cathepsin L have been described to process SARS-CoV (Simmons
et al., 2005) and this appears to be maintained for SARS-CoV-2
(Hoffmann et al., 2020), although the significance of such intracellular
proteinase activity is unclear. Potent inhibitors for these two protein-
ases have been reported as pharmacological probes, but there are no
licensed drugs identified to target them.
Following entry into the cell, many viruses accumulate in acidified
lysosome-like vesicles and so weak bases (including ammonium chlo-
ride and chloroquine), which target the lysosome have been used
in vitro to target this mechanism. Ammonium chloride (at 20 mM) has
been described as a non-specific inhibitor of viral replication in vitro,
targeting viral uncoating (Mizzen, Hilton, Cheley, & Anderson, 1985)
and, at 50 mM, ammonium chloride inhibited cell entry of both SARS-
CoV and SARS-CoV-2 (Hoffmann et al., 2020). Chloroquine was also
observed to reduce infection of L cells by mouse hepatitis virus
3 (Krzystyniak & Dupuy, 1984).
4.2 | Viral replication
Following entry into the cell, the virus subverts nucleotide, protein,
lipid, and carbohydrate turnover of the host cell to produce multiple
copies of itself. The viral RNA is translated into multiple proteins to
produce the replication machinery. As protein translation from the
viral genome occurs, the two polyproteins are the first to be synthe-
sized, with the two intrinsic proteases able to cleave the polyproteins
into their constituent products.
4.2.1 | Targeting the viral proteinases
The low sequence similarities between mammalian and viral
proteases has allowed successful drug targeting of viral diseases,
including both HIV/AIDS and HCV/hepatitis C. The genome of
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SARS-CoV-2 contains two proteinases intrinsic to the polyproteins,
PLpro and 3CLpro.
4.2.1.1 | The papain-like proteinase of the virus
(PLpro)
The more N-terminally located PLpro is the larger (2,000 aa)
of the two proteins (for review, see Baez-Santos, St John,
& Mesecar, 2015; Lei, Kusov, & Hilgenfeld, 2018) and in SARS-
CoV is a membrane-associated, polyfunctional entity (Harcourt
et al., 2004). Sequence modelling of SARS-CoV-2 PLpro suggested
the presence of 6 TM domains towards the C-terminus, with the
majority of the protein extending into the cell cytoplasm (Angeletti
et al., 2020). In other coronaviruses, the enzyme is also capable of
hydrolysing ubiquitin from protein substrates (Barretto et al., 2005;
Ratia et al., 2006), as well as removing the ubiquitin-like protein
IFN-stimulated gene 15 (ISG, Link to UniProt) from ISG-conjugated
proteins (Yang et al., 2014). Using the orthologous proteinase from
the mouse hepatitis coronavirus, analysis of three distinct structural
domains suggested that the PLpro domain coincided with the
deubiquitinylating and deISGylating functions (Chen et al., 2015). In
SARS-CoV, the PLpro also contains an ADP-ribose-100-phosphatase
functional phosphatase domain directed at ADP-ribose-100-
phosphates, although the functional significance of the hydrolase
activity may be less impactful than the capacity to bind ADP-
ribose, at least for the enzyme from HCoV-229E (Putics, Filipowicz,
Hall, Gorbalenya, & Ziebuhr, 2005). This domain is thought to con-
tribute to processing of the viral subgenomic RNAs and the
suppression of the innate immune system through reducing IFN
production (Lei et al., 2018).
Investigating the peptidase activity of SARS-CoV PLpro suggested
a preference for larger proteins (ubiquitinated or ISGylated) rather
than simpler fluorescent-tagged oligopeptide substrates (Baez-Santos,
Mielech, Deng, Baker, & Mesecar, 2014; Lindner et al., 2005; Lindner
et al., 2007; Ratia, Kilianski, Baez-Santos, Baker, & Mesecar, 2014)
making screening more complicated.
4.2.1.2 | The chymotrypsin-like proteinase, 3C-like
proteinase of the virus (3CLpro)
The smaller proteinase from SARS-CoV-2 is 3CLpro (sometimes
called the main prote(in)ase, Mpro). The use of in silico docking
models of SARS-CoV-2 3CLpro has led to suggestions that particu-
lar existing antiviral agents, including velpatasvir and ledipasvir
(licensed agents for treating hepatitis C when combined with
sofosbuvir in the United Kingdom), should be screened for func-
tional activity (Chen, Yiu, & Wong, 2020). A recent screen of
10,000 compounds including approved drugs, candidate drugs
and natural products used a substrate derived from the N-terminal
autocleavage site of the SARS-CoV-2 3CLpro, which was modified
(methylcoumarinylacetyl-AVLQSGFR-Lys (Dnp)-Lys-NH2) to allow a
FRET-based assay (Jin et al., 2020). The same substrate was used
in a screen of the equivalent enzyme from another coronavirus,
HCoV-HKU1, which transferred to humans (Zhao et al., 2008).
A number of inhibitors of the SARS-CoV 3CLpro proteinase have
been described (Goetz et al., 2007; Lu et al., 2006; Yang et al., 2006),
without progressing into the clinic. Recently, an in silico approach
using orthologues of the SARS-CoV 3CLpro from other coronaviruses
and enteroviruses allowed production and testing in vitro of a series
of α-ketoamides (Zhang et al., 2020). One compound (11r) exhibited
submicromolar potency against SARS-CoV 3CLpro in a cell-free FRET-
based assay and micromolar potency in a cell infection assay with
SARS-CoV (Zhang et al., 2020).
In a very recent report, the SARS-CoV-2 3CLpro expressed in
HEK293 cells was found to interact with histone deacetylase
2 (HDAC2) by affinity purification/MS (Gordon, Jang, et al., 2020). A
number of approved drugs target HDAC2 in the treatment of various
T cell lymphomas, including romidepsin, belinostat and vorinostat
with nanomolar potency (Bradner et al., 2010).
4.2.2 | Targeting nucleotide turnover
A relatively large proportion of the viral genome is inevitably
devoted to nucleotide turnover. For SARS-CoV-2, this includes
nsp7/nsp8/nsp12 as an RNA-dependent RNA polymerase, nsp13
as a helicase, nsp10/nsp14 as an 30-to-50 exonuclease complex,
nsp15 as an endoribonuclease and nsp16 as a 20-O-ribose
methyltransferase.
Remdesivir (currently in clinical trials to treat COVID-19) is
described as a non-selective inhibitor of multiple RNA viruses and has
shown some efficacy in MERS-CoV and SARS-CoV infection of mon-
keys (de Wit et al., 2020). In in vitro investigations, the triphosphate
analogue of remdesivir inhibited RNA synthesis of MERS-CoV RNA-
dependent RNA polymerase (primarily nsp8/nsp12 complexes derived
from co-expression in insect cells of a construct containing nsp5,
nsp7, nsp8, and nsp12) with an IC50 value of 32 nM when nucleotide
levels were low, increasing to 690 nM at higher nucleotide concentra-
tions (Gordon, Tchesnokov, Feng, Porter, & Gotte, 2020). In silico
modelling identified that remdesivir, as well as the approved antiviral
drugs ribavirin, sofosbuvir, and tenofovir, could bind tightly to the
active site of nsp12 from SARS-CoV-2, based on the crystal structure
of SARS-CoV (Elfiky, 2020).
However, ribavirin alone had no significant effect in a clinical trial
with SARS patients, although a combination of ribavirin with
lopinavir–ritonavir and corticosterone had a lower rating of acute
respiratory distress syndrome and death (for review, see Zumla
et al., 2016). In-depth analysis has not been completed with MERS
patients, although an ongoing Phase 2 clinical trial for MERS uses a
combination therapy of lopinavir/ritonavir and IFN-β1b (Arabi
et al., 2020).
Nsp13 is a helicase, which enables unwinding of duplex RNA. The
exoribonuclease activity of nsp14 sets the coronaviruses apart
(Snijder et al., 2003), as the enzyme is suggested to remove damaging
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mutations from the genome (Eckerle et al., 2010; Sevajol, Subissi,
Decroly, Canard, & Imbert, 2014). In other coronaviruses, the end-
oribonuclease nsp15 has some selectivity for hydrolysing polyU
sequences (Hackbart, Deng, & Baker, 2020). This enables the virus to
delay or minimize initiation of the innate immune system by hydro-
lysing negative sense polyU nucleotides, which activate the MDA5
system to evoke intereferon production (discussed further below).
Nsp16 is a methyltransferase, which uses S-adenosyl-L-methionine as
a co-substrate to assist in cap formation (Decroly et al., 2008).
4.2.2.1 | Protein:protein interactions in recombinant
expression
In a very recent report, a series of tagged recombinant proteins from
SARS-CoV-2 were expressed in HEK293 cells and then protein part-
ners were identified by affinity purification/MS (Gordon, Jang,
et al., 2020). For nsp12 (RNA-dependent RNA polymerase) and nsp14
(30-50-exonuclease) of SARS-CoV-2, interactions with receptor inter-
acting protein kinase 1 (RIPK1) and inosine monophosphate dehydro-
genase 2 (IMPDH2) respectively, were identified. For these two
targets, there are established approved drugs. Thus, ponatinib, which
is used to treat acute myelogenous leukaemia or chronic myelogenous
leukaemia (Philadelphia chromosome), targets multiple protein
kinases, inhibiting RIPK1 with an IC50 value of 12 nM (Najjar
et al., 2015). Mycophenolic acid and ribavirin are IMPDH2 inhibitors
with IC50 values of 20 nM (Nelson, Eugui, Wang, & Allison, 1990) and
1-3 μM (Wittine et al., 2012) ranges, respectively, with clinical uses in
organ transplantation and antiviral therapy, respectively.
Reservations about the use of ribavirin have already been noted
above. Mycophenolic acid as a monotherapy was examined in a MER-
CoV-infected non-human primate model, where the authors con-
cluded it actually worsened the condition (Chan et al., 2015).
Nsp13 (helicase) and nsp15 (endoribonuclease) have been
described to bind to centrosome-associated protein 250 (CEP250)
and RNF41 (also known as NRDP1, Link to UniProt) respectively, in a
report of recombinant expression (Gordon, Jang, et al., 2020). CEP250
is suggested to influence centrosome cohesion during interphase
(de Castro-Miro et al., 2016) and to be elevated in peripheral T cell
lymphomas (Cooper et al., 2011). The functional relevance of nsp13
interaction with CEP250 is not yet clear. RNF41 is an E3 ubiquitin
ligase, which polyubiquitinates myeloid differentiating primary
response gene 88 (MyD88, link to UniProt), an adaptor protein for
Toll-like receptors, which allows activation of TBK1 and IRF3 (see
below) and thereby increases type I IFN production (Wang
et al., 2009).
4.2.3 | Targeting phospholipid turnover
The lipid profile of viruses appears to be important in terms of viral
entry into the cell, either as sites for anchoring or for endocytosis
(for review, see Heaton & Randall, 2011; Mazzon & Mercer, 2014).
Replication of SARS-CoV is reported to take place associated with
the endoplasmic reticulum in “replicative organelles” incorporating
convoluted membranes and interconnected double-membrane vesi-
cles, inferring a capacity for the virus to induce extensive reorganiza-
tion of intracellular phospholipid membranes (Knoops et al., 2008).
Three non-structural proteins from SARS-CoV with transmembrane
domains, nsp3 PLpro (see above), nsp4 and nsp6 when co-expressed
in model cells prompted the formation of these double-membrane
vesicles (Angelini, Akhlaghpour, Neuman, & Buchmeier, 2013),
although it is unclear whether specific catalytic activities are
necessary for this action.
The lipidome of influenza virus (also a positive strand RNA virus)
consists of glycerophospholipids, sterols (mainly cholesterol) and
sphingolipids, with sphingolipids and cholesterol enriched compared
to the host cell membrane (Gerl et al., 2012), but there does not yet
appear to be a parallel investigation of SARS-CoV.
Cytosolic phospholipase A2α (cPLA2α) hydrolyses phospholipid to
produce lysophospholipids and free fatty acids. Using
alphacoronavirus HCoV-229E-infected Huh-7 cells, inhibition of
cPLA2α using pyrrolidine-2 at higher concentrations (20 μM) evoked
an inhibition of viral titre (Muller et al., 2018). Arachidonoyl
trifluoromethylketone, a non-selective inhibitor of multiple
eicosanoid-metabolizing enzymes including PLA2 isoforms, also
inhibited viral titres at higher concentrations (Muller et al., 2018).
Transmission electron microscopy suggested that cPLA2α inhibition
reduced the density of double-membrane vesicles (Muller
et al., 2018). Analysis of lipid metabolites indicated that HCoV-229E-
infected Huh-7 cells showed increases in levels of ceramides,
lysophospholipids and phosphatidylglycerols, with decreases in
phosphatidic acids (Muller et al., 2018). 20-μM pyrrolidine-2 inhibited
the elevations in lysophospholipids and phosphatidylglycerols, but not
the ceramides. Intriguingly, some selectivity of the involvement of
PLA2α was suggested as pyrrolidine-2 also displayed antiviral activities
against other members of the Coronaviridae (and Togaviridae) families,
while members of the Picornaviridae family were not affected.
Although speculative, there is the possibility that some of the
benefits of glucocorticoid administration in the clinic might be the
up-regulation of annexins and the subsequent binding and conceal-
ment of membrane phospholipid from further metabolism (for
review, see Lemmon, 2008). While clearly some distance from a val-
idated target, targeting the host availability of key structural (pho-
spho)lipids, particularly sphingolipids, has been proposed to be a
useful strategy in preventing propagation of enveloped human RNA
viruses, including influenza, HIV and hepatitis C (Yager &
Konan, 2019). Currently, however, assays to screen inhibitors of
cPLA2α are relatively limited.
4.2.4 | Targeting carbohydrate turnover
Given that a number of the viral proteins, including the two structural
proteins spike and membrane, are glycoproteins, there is clearly a
diversion of sugars from the host. It is unclear as yet whether specific
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sugars are involved and whether specific host glycosyltransferases are
involved in the processing of coronavirus glycoproteins and might,
therefore, form further tractable targets for drug discovery. Notably,
in studies using site-directed mutagenesis of the spike protein from
SARS-CoV, glycosylation was identified at three glutamine residues
within the S1 region, with no loss of binding to ACE2-expressing cell
of mutated (non-glycosylated) fragments (Chakraborti, Prabakaran,
Xiao, & Dimitrov, 2005).
5 | THE OTHER VIRAL STRUCTURAL PROTEINS
5.1 | The envelope protein E
The envelope proteins of SARS-CoV, HCoV229E and MERS are small
(<100 aa) single transmembrane domain proteins (see Figure 2) and
constitute ion channels with selectivity for monovalent cations over
monovalent anions (Wilson, McKinlay, Gage, & Ewart, 2004; Zhang
et al., 2014) apparently forming homopentamers in model membranes
(Pervushin et al., 2009; Surya, Li, Verdia-Baguena, Aguilella, &
Torres, 2015). Infecting or transfecting the coronavirus E message
into cells results in accumulation of protein in the Golgi region (Ruch
& Machamer, 2012). Conserved cys residues proximal to the trans-
membrane domain internally within the virus are palmitoylated
(Lopez, Riffle, Pike, Gardner, & Hogue, 2008), a post-translational
modification suggested to allow an internal inflexion point in the pro-
tein (Ruch & Machamer, 2012).
Hexamethylene-amiloride has been described as an inhibitor of
the HIV-1 virus Vpu ion channel (Ewart, Mills, Cox, & Gage, 2002) and
to reduce virus proliferation in human macrophages in culture (Ewart
et al., 2004). Hexamethylene-amiloride, but not the clinically used
amiloride, inhibited the SARS-CoV envelope protein-associated ion
channel activity when expressed in HEK293 cells (Pervushin
et al., 2009).
Amantadine has had multiple uses clinically, including in the ther-
apy of Parkinson's disease (for review, see Vanle et al., 2018). It has
been used to treat influenza A infection through targeting the M2 ion
channel (Holsinger, Nichani, Pinto, & Lamb, 1994; Pinto, Holsinger, &
Lamb, 1992; Wang, Takeuchi, Pinto, & Lamb, 1993), although it is no
longer recommended in the United Kingdom or United States because
of drug resistance (for review, see Li, Chan, & Lee, 2015). Amantadine
at higher concentrations (100 μM) was found to inhibit the SARS-CoV
E protein expressed in model membranes (Torres et al., 2007).
SARS-CoV E protein was identified as being pro-apoptotic upon
transfection into Vero E6 monkey epithelial cells, where it localized to
both plasma membrane and punctate cytoplasmic locations (Chan
et al., 2009). Indeed, the SARS-CoV E protein's ion channel function
has been linked to calcium entry into endoplasmic reticulum/Golgi
membrane complexes and the subsequent activation of the NLRP3
inflammasome, leading to IL-1β production (Nieto-Torres et al., 2015).
siRNA targeting of the envelope protein of SARS-CoV reduced
virus release in culture media, without altering N and P gene expres-
sion in FRhK-4 monkey kidney epithelial cells (Lu et al., 2006). A
similar observation was reported for the ORF4a protein (derived from
the Orf4a gene) of HCoV229E (Zhang et al., 2014). Infecting mice with
SARS-CoV in which the E protein ion channel function was disrupted
showed unchanged viral proliferation but reduced IL-1β and oedema
levels in the lungs and better survival over 10 days post-infection
(Nieto-Torres et al., 2014).
In a very recent report, the E protein of SARS-CoV-2 has been
reported to interact with BRD2/BRD4 BET family bromodomain
kinases when expressed in HEK293 cells (Gordon, Jang, et al., 2020).
JQ1 and RVX208 are BRD2/4 inhibitors with IC50 values with
40-120and 50-1,800nM ranges respectively.
5.2 | The membrane protein M
The membrane protein is usually regarded as the most abundant pro-
tein in the coronavirus envelope (see Figure 2) and is of intermediate
size in SARS-CoV-2 (222 aa). It is thought to assist in viral assembly
by collating the other surface structural proteins (Ruch &
Machamer, 2012).
5.3 | The nucleocapsid phosphoprotein N
The N protein is of moderate size in SARS-CoV-2 (419 aa), highly
basic and binds the viral RNA as a dimeric entity (Fan et al., 2005)
into nucleocapsids (see Figure 2), which afford protection for the
viral genome, while also providing access for replication at appropri-
ate times (for review, see McBride, van Zyl, & Fielding, 2014). In a
very recent report, the N protein of SARS-CoV-2 was tagged and
expressed in HEK293 cells and then protein partners were identified
by affinity purification/MS (Gordon, Jang, et al., 2020). The N pro-
tein was suggested to interact with casein kinase 2 (CK2), La-related
protein 1 (LARP1, Link to UniProt) and stress granule protein Ras
GTPase-activating protein-binding protein 1 (G3BP1, Link to
UniProt). CK2 phosphorylates a broad range of cellular targets,
mostly in the nucleus, to regulate development and differentiation
(for review, see Gotz & Montenarh, 2017). Although not in use clini-
cally, two inhibitors are described to target CK2 with high affinity.
Silmitasertib is a CK2 inhibitor with an IC50 value of 1 nM (Pierre
et al., 2011), while TMCB has a Ki value of 21 nM (Janeczko,
Orzeszko, Kazimierczuk, Szyszka, & Baier, 2012). LARP1 is an RNA-
binding protein, which releases RNA when phosphorylated by
mTORC1 (Fonseca et al., 2015; Hong et al., 2017). LARP1 seems to
preferentially bind 50-terminal oligopyrimidines with an as-yet
unclear cellular role (Philippe, van den Elzen, Watson, &
Thoreen, 2020). Of the three targets suggested to associate with
SARS-CoV-2 N phosphoprotein, G3BP1 seems a relevant focus for
therapy against COVID-19. G3BP1 regulates the innate immune
response (Kim, Sze, Liu, & Lam, 2019; Liu et al., 2019; Wiser, Kim,
& Ascano, 2019; Yang et al., 2019) and stress granules reduce the
replication of MERS-CoV (Nakagawa et al., 2018), so there is a
potential for targeted drug discovery.
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6 | INTERACTIONS WITH THE HOST INNATE
IMMUNE SYSTEM
SARS-CoV produces proteins that interfere with IFN pathways
(nsp1, nsp3, nsp16, ORF3b, ORF6, ORF9b, M and N proteins
Wong, Lui, & Jin, 2016) and NLRP3 inflammasome activators (E,
ORF3a, and ORF8b), which are closely related to orthologues
found in SARS-CoV-2. Fung, Yuen, Ye, Chan, and Jin (2020) have
recently reviewed the molecular aspects whereby SARS-CoV and,
by inference SARS-CoV-2, evade immune surveillance, activate the
inflammasome and cause pyroptosis. Other coronaviruses may give
an indication as to how this is happening. HCoV-229E rapidly kills
dendritic cells, while monocytes are much more resistant. The rapid
invasion of and replication in dendritic cells kills them within a few
hours of infection (Mesel-Lemoine et al., 2012). Dendritic cells are
sentinel cells in the respiratory tract and plasmacytoid dendritic
cells are a crucial antiviral defence via IFN production and by
modifying antibody production. Thus, these viruses can impair
control of viral dissemination and the formation of long-lasting
immune memory. Penetration of SARS-CoV-2 infection deep into
the lungs and eventually the alveolae, results in the “cytokine
storm”, which accompanies pneumonia and lung fibrosis and is
probably a major determinant of the necessity for intubation and
also mortality (Shi, Wang, et al., 2020). It is currently not known
what specific factor/s differentiate the patients who develop this,
although mortality among younger health workers may indicate
that initial viral load may play a role. Immunological agents, which
can prevent or control the “cytokine storm” could therefore have a
major effect on necessity to intubate and mortality. Tocilizumab is
a monoclonal antibody targeting IL-6 receptors, as a means to
interfere with the effects of chronic autoimmune disorders such as
rheumatoid arthritis. The Chinese Clinical Trials Registry has two
studies that are designed to evaluate tocilizumab efficacy in
patients with severe COVID-19 pneumonia (Registration Numbers
ChiCTR2000029765 and ChiCTR2000030442). Similarly, anakinra,
which is a slightly modified version of an endogenous antagonist
of IL-1 receptors, is being investigated in clinical trials in multiple
locations in patients with COVID-19 infection (NCT04324021,
NCT04330638, and NCT02735707).
It has been reported that in stage III of COVID-19, a critical point
with a high viral load and severe respiratory involvement, lungs of
patients appear with “ground-glass” patches in CT scans, while
autopsy reports indicate that the lungs are filled with a “clear liquid
jelly” (Shi, Wang, et al., 2020; Xu et al., 2020), similar to an observa-
tion in drowning victims. On the hypothesis that inflammation-driven
hyaluronan production (via hyaluronan synthase 2 [HAS2] Link to
UniProt) and associated water retention may be critical. A recent
study proposed therapy via administration of recombinant hyaluroni-
dase or inhibitors of HAS2 (Shi, Wang, et al., 2020).
The interaction between the virus and the innate immune system
is complex and multifactorial, with temporal intricacies. It is beyond
the scope of this review to identify all the multiple components and
so we discuss here those pathways we consider most tractable.
6.1 | Viral nucleotides and MDA5/MAVS/IFN
production
The positive sense RNA of coronaviruses is translated to produce the
replication machinery, which allows complementary negative sense
RNA to be synthesized, which itself is the template for the synthesis
of positive strand RNA. As a consequence, double-stranded RNA is
produced, which act as a pathogen-associated molecular pattern
(PAMP) targeting MDA5 (IFN induced with helicase C domain I, also
known as melanoma differentiation antigen 5, Kato et al., 2006) from
the RIG-1-like receptor family of cytoplasmic pattern recognition
receptors (for reviews, see Schlee, 2013; Bryant et al., 2015). MDA5
differs from RIG-1 (DexD/H-box helicase 58, also known as retinoic
acid-inducible gene 1) in recognizing longer dsRNA (Goubau
et al., 2014; Kato et al., 2006), and it has been proposed that this dif-
ferentiates the sensing of positive-stranded viruses by MDA5 com-
pared to negative strand virus sensing by RIG-I (Goubau, Deddouche,
& Reise Sousa, 2013; Kato et al., 2006). RIG-1-like receptors have an
N-terminal caspase activation and recruitment domain (CARD), which
shows ligand-dependent interaction with CARDs from other proteins,
such as mitochondrial antiviral signalling protein (MAVS, Link to
UniProt). MAVS activates IKK family kinases, such as TANK binding
kinase (TBK1) and IKK-ε, leading to the phosphorylation of IFN regu-
latory factors, such as IRF3 (Link to UniProt) and IRF7 (Link to
UniProt). This induces the transcription of Type I IFN genes, such as
IFN-β and CCL5 (also known as RANTES) (Doyle et al., 2002; Fitzger-
ald et al., 2003; Sharma et al., 2003). MAVS present in peroxisomes is
also able to recruit short-acting, IFN-independent defence factors
(Dixit et al., 2010).
The ORF9b protein from SARS-CoV has also been reported to
target mitochondrial MAVS to limit the IFN response, as well as
triggering proteolysis of dynamin-like protein 1 (Link to UniProt)
thereby prompting the formation of mitochondria-associate
autophagosomes claimed to create “havoc” in energy production in
infected cells (Shi et al., 2014). In a very recent study, ORF9b of
SARS-CoV-2 has been reported to interact with translocases of
outer membrane 70 (Tom70, Link to UniProt) when expressed in
HEK293 cells (Gordon, Jang, et al., 2020) Tom70 activates mito-
chondrial IRF3 (Liu, Wei, Shi, Shan, & Wang, 2010) and so this is a
potential locus for pharmacological intervention, but as yet with no
inhibitors described in the literature.
A number of other coronavirus proteins have been identified to
influence the IRF3 pathway to restrict IFN production. This includes
the MERS-CoV PLpro proteinase (Yang et al., 2014), as well as the
ORF6 and nucleocapsid proteins from SARS-CoV (Kopecky-Brom-
berg, Martinez-Sobrido, Frieman, Baric, & Palese, 2007). The ORF6
protein of SARS-CoV has also been described to reduce the activity of
a series of karyopherin-dependent host transcription factors (Sims
et al., 2013). Karyopherin is an importin, which traffics proteins
between the cytoplasm and the nucleus (for review, see Kosyna &
Depping, 2018; Guo, Fare, & Shorter, 2019).
Clearly, the induction and suppression of IFN production are cen-
tral to numerous human diseases and have been extensively studied;
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the 'trick' to treat COVID-19 will be to identify a novel angle for ther-
apeutic exploitation.
6.2 | Nsp1
Working with SARS-CoV (not SARS-CoV-2), Pfefferle et al. (2011)
used yeast two-hybrid screens to identify interactions between the
viral and human proteomes. They identified an interesting
interaction between viral Nsp1 and a group of host peptidyl-prolyl
cis-trans-isomerases (PPIA, PPIG, PPIH and FKBP1A, FKBP1B), all
of which modulate the calcineurin/NFAT pathway important in
immune activation (reviewed by Hogan, Chen, Nardone, &
Rao, 2003). The nsp1 protein acts on these to activate NFAT sig-
nalling and immune activation. Cyclosporine A, an inhibitor of this
pathway, has been used for several decades to control transplant
rejection and some autoimmune diseases and, in a simple in vitro
assay, cyclosporine inhibited SARS-CoV transcription/replication in
(non-immune-system) cells (Pfefferle et al., 2011). SARS-CoV-2 has
an nsp1 protein closely related to that of SARS-CoV (Dong
et al., 2020; Srinivasan et al., 2020), though its effect on the NFAT
pathway seems not to have been reported. Nevertheless, cyclo-
sporine has been shown to inhibit SARS-CoV2 in an in vitro Vero
cell-based assay in a recent report (Jeon et al., 2020). It has there-
fore been suggested as a drug target (see, for example, Li & De
Clercq, 2020). It may seem paradoxical to suggest an inhibitor of
immune activation as a treatment for viral disease, but for the sub-
group of patients that might suffer cytokine storms (Mehta
et al., 2020), the double-action might be useful.
6.3 | ORF3a, ORF6, ORF8 and other viral proteins
The ORF3a protein of SARS-CoV appears to bind calcium in a cyto-
plasmic domain (Minakshi, Padhan, Rehman, Hassan, & Ahmad, 2014)
and to elicit a response from the innate immune system by enhancing
the ubiquitination of apoptosis-associated speck-like protein con-
taining a CARD (Asc, Link to UniProt), which in turn activates the
NLRP3 inflammasome and caspase 1 (Siu et al., 2019). The potential
for targeting Asc and the NLRP3 inflammasome for therapeutic bene-
fit in inflammatory conditions has recently been reviewed (Mangan
et al., 2018), although there are no inhibitors in the clinic as yet.
In SARS-CoV, the Orf8a and Orf8b genes became separated as
the disease progressed by a 29-nucleotide deletion (Chinese SARS
Molecular Epidemiology Consortium, 2004; Oostra, de Haan, &
Rottier, 2007). The Orf8a gene of SARS-CoV encodes a short (31 aa,
1 TM, Link to UniProt) protein, which forms a cation channel of
predicted pentameric structure (Chen et al., 2011). In SARS-CoV-2
and a bat-derived coronavirus, in contrast to the SARS-CoV-2
genome, Orf8 encodes a continuous 121 aa ORF8 protein (Cagliani,
Forni, Clerici, & Sironi, 2020). Given that sequence analysis of differ-
ent strains of SARS-CoV-2 suggests that the Orf8 locus displays only
limited evidence of positive selection (Cagliani et al., 2020), it seems
germane to investigate the profile of ORF8 protein in more depth.
Sequence comparisons led to prediction of secondary structure com-
posed of an α-helix and a β-sheet containing six strands (Chan
et al., 2020), but there appears not to be any literature as to whether
this entity is a functional ion channel.
In a very recent report, the ORF14 protein (Link to UniProt) of
SARS-CoV-2 has been reported to interact with NOD-like receptor
X1 (NLRX1), proteinase-activated receptor 2 (PAR2/F2RL1), and
NEDD4 family-interacting protein 2 (NDFIP2, Link to UniProt), among
other proteins of the IκB/NF-κB pathway, when expressed in
HEK293 cells (Gordon, Jang, et al., 2020). At the moment, there are
no approved drugs targeting PAR2, although AZ3451 (Link to GtoP)
acts as a negative allosteric modulator with pIC50 values of 5–23 nM
(Cheng et al., 2017).
There is a limited insight into the roles or potential exploitability
of the remaining range of other viral proteins (nsp2; nsp9; nsp11, pro-
teins Orf3b; ORF6; ORF7a; ORF7b; ORF10).
7 | ANIMAL MODELS OF SARS-COV-2 INFECTION
The spike glycoproteins in SARS-CoV and MERS-CoV are crucial for
host specificity and jumping between species, for example, from bats
to humans (Lu, Wang, & Gao, 2015) and from dromedary camels to
humans (MERS-CoV) and also the recent crossover of a HKU2-related
coronavirus to pigs as a swine acute diarrhoea syndrome (SADS-CoV)
(Zhou et al., 2018). SADS-CoV appears to influence the innate
immune system by reducing IFN-β production evoked through IPS-1
and RIG-I pathways, but not through IRF3, TBK1 and IKKε (Zhou
et al., 2020).
ACE2, as an anchoring point for the spike glycoprotein, is present
throughout the animal kingdom, but small structural differences are
critical for interaction with the spike protein (Li, Qiao, & Zhang, 2020;
Luan, Lu, Jin, & Zhang, 2020). Key sequences of the spike protein
from SARS-CoV and SARS-CoV-2 are responsible for binding to
ACE2. Luan et al. (2020) found that the key residues in S protein, from
SARS-CoV and SARS-CoV-2, recognized in ACE2 from dog, cat, pan-
golin and Circetidae mammals (simulated through homology modelling)
were broadly similar. Mouse ACE2 is inefficient in prompting entry of
both SARS-CoV and SARS-CoV-2 (Fung et al., 2020). Cats and dogs
suffer from their own specific coronavirus infections (e.g. canine respi-
ratory coronavirus and feline coronavirus) without significant cross-
over to humans. A very recent report has suggested that cats and
ferrets are sensitive to SARS-CoV-2, but dogs, pigs, chickens and
ducks are much less sensitive (Shi, Wen, Zhong, Yang, Wang, Huang,
Liu, He, Shuai, Sun, & Zhao, 2020). Ferrets, which have previously
been used as models for respiratory tract infections, retained the
SARS-CoV-2 virus in the respiratory tract, while the infection was
transmitted between cats by aerosol (which may have implications for
confinement); infected cats subsequently produced antibodies (Shi,
Wen, et al., 2020).
The Syrian hamster has been used as a model for SARS-CoV
(de Wit et al., 2013; Roberts et al., 2005; Roberts et al., 2006) and
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studies with mice and Syrian hamsters are ongoing with SARS-CoV-2.
In a small study where three juvenile (3–5 years old) and two mature
(15 years old) rhesus macaques were infected intratracheally with the
SARS-CoV-2 virus, all the monkeys showed symptoms of inflamma-
tion and interstitial pneumonia, with a greater apparent severity in the
older animals (Yu et al., 2020).
Thus, while there is intensive research in animal models, a clearly
validated model is still not apparent.
8 | INTER-INDIVIDUAL VARIATIONS IN
SUSCEPTIBILITY
Given the similarities in the viruses and their symptoms, there is
clearly a value to comparing the profiles of sufferers from the original
SARS and subsequent MERS outbreaks with COVID-19 to evaluate
the risk factors associated with each event individually and collec-
tively. A detailed consideration is beyond the scope of this review, but
there are some obvious questions to ask (not in an order of priority).
1. What factor/s determine resistance to infection?
It is apparent that many individuals who test positive for SARS-
CoV-2 infection only experience 'mild'symptoms, others suffer a
level of debilitation requiring hospitalization with limited supervi-
sion and a third group requires assisted breathing.
2. Is blood group a predictor?
There is preliminary evidence (as yet, not peer-reviewed)
suggesting that people with type A blood might be more at risk of
COVID-19 than those with other blood types (Zhao et al., 2020).
3. Are there 'simple' genetic markers which predict this variation?
For example, are single nucleotide polymorphisms/haplotypes for
key targets (including ACE2, TMPRSS2, etc., Delanghe, Speeckaert,
& De Buyzere, 2020) associated with higher or lower damage in
humans infected with SARS-CoV, MERS-CoV, or SARS-CoV-2?
4. Reports suggest that there is a preponderance of male victims of
COVID-19, for example in Spain (Instituto de Salud Carlos III, Min-
istry of Science & Innovation, Spain. Retrievedon 2020-03-25,
referring to data from 2020-03-24). What might be the cause of
this sexual divergence?
5. Is smoking history a predictor of variation?
One potential explanation for the relatively high proportion of
male victims has been suggested to be previous smoking history
(Cai, 2020; Olds & Kabbani, 2020; Vardavas & Nikitara, 2020),
clearly a general risk factor for many diseases. Is there evidence
from the SARS and MERS outbreaks to suggest a commonality of
susceptibility?
6. What is the impact of contracting the virus on individuals with
other underlying conditions?
For example, what are the mechanism/s underlying why some
sufferers of hypertension and/or diabetes might be at higher
risk (https://www.immunopaedia.org.za/breaking-news/why-are-
hypertension-and-diabetes-patients-at-high-risk-of-severe-covid-
19/)? Is there evidence that patients on ACE inhibitors or
angiotensin receptor antagonists were at higher risk with SARS-
CoV and MERS-CoV infections and, currently, for SARS-CoV-2
infection?
7. How will the evolution of the virus alter rates of infection and the
severity of symptoms?
Some level of mutation is to be expected and indeed has been
noted for the SARS-CoV-2. At the moment, it is too early to iden-
tify the significance of any influence of these mutations on the
course of COVID-19.
Some of these questions are more tractable since the SARS and
MERS outbreaks because of the strides being made in sophisticated
molecular biological techniques (e.g. NextGen Sequencing). An addi-
tional distinction compared to the previous outbreaks is the major
increase in patient numbers associated with COVID-19, allowing
greater comparisons to be made in many more geographical locations.
Inevitably, other questions will form as greater detail becomes
available.
9 | CONCLUSION AND
RECOMMENDATIONS
This review has concentrated on the prevailing hypothesis that an
essential first step in infection is SARS-CoV-2 binding to ACE2 and
for TMPRSS2 to prime the viral spike protein. We further hypothesize
that both proteins must be expressed on a target cell for the virus to
gain entry. TMPRSS2 has an extensive cellular expression profile,
whereas ACE2 is more limited and is usually at low levels, unless
increased by risk factors such as sex, age and smoking history, so is
likely to be rate-limiting. Other potential target proteins such as
cathepsin L or B0AT1 may also prove important.
Currently, although there are no drugs approved for the treat-
ment of patients with COVID-19, the pandemic has triggered a stam-
pede into clinical trials with both approved and investigational agents.
The pharmacological rationale for these trials is sometimes obscure,
but there is a logic to focus on viral entry and replication, as well as
limiting the host immune response.
For the immediate term, the highest priority would be to investi-
gate known antivirals to mitigate effects of COVID-19. For the longer
term, a vaccine (for review, see Amanat & Krammer, 2020) seems to
hold the most promise to reduce COVID-19 damage. There is also a
role in the mid-term, however, for drug discovery conducted in main-
stream pharmacology labs. The goal here would be an international
co-ordinated approach to drug repurposing, examining the spectrum
of licensed drugs (likely to be less than 2,000, varying dependent on
jurisdictions). These would ideally be screened in a co-ordinated,
blinded fashion in multiple labs simultaneously to account for any
minor methodological differences. This requires the reopening of
screening and protein biosynthesis labs closed at the start of the pan-
demic, while ensuring that workers are kept safe.
If one were to write a Target Product Profile for a drug to treat
COVID-19, several parallel profiles can be identified. There are clear
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considerations, which may be identified as desirable pharmacody-
namic, screening methodologies, drug metabolism and pharmacoki-
netic and formulation profiles.
From a pharmacodynamic perspective, a priority would be to
screen the proteinases identified in this review (ACE2, TMPRSS2,
ADAM17, cathepsin L, cathepsin B, PLpro and 3CLpro). A second paral-
lel stream would assess inhibitors of the viral RNA polymerase and
endoribonuclease complexes, as well as the ion channel functions of
the viral envelope (and potentially the Orf8 protein). Clearly, there are
multiple other targets, which might bear fruit, and so further studies
should assess the tractability of B0AT1/SLC6A19, B0AT3/SLC6A18,
IMPDH2 and HAS2. Further, the molecular mechanism of action of
ivermectin should be assessed, since it has recently been shown to
inhibit in vitro SARS-CoV-2 replication (Caly, Druce, Catton, Jans, &
Wagstaff, 2020). This agent is used clinically as an anthelmintic, prob-
ably through blocking invertebrate glutamate receptors although it
also inhibits mammalian glycine receptors and acts as a positive allo-
steric modulator of other mammalian ligand-gated ion channels.
From a screening aspect, biophysical and biochemical screens
would probably take a matter of days to weeks. Following mass avail-
ability of the recombinant proteins involved, the capacity for inhibi-
tion should be assessed using a library of already approved drugs.
Biophysical methods can be applied, such as surface plasmon reso-
nance or biolayer interferometry, to monitor the affinity of interaction
between host ACE2 and viral spike glycoprotein in the presence of
these agents, as well as the relevant proteins where multimerization is
critical, such as the trimeric spike glycoprotein. Assessing the remain-
der of the targets would likely adopt standard, fluorescent-based
pharmacological approaches.
If the assay involves the use of viral proteins, the constructs
should acknowledge the inevitable mutations which the viral genome
has/will undergo.
An overarching priority for the in vitro screening would be to
recognize and replicate, as much as possible, relevant features of
the virus and its life cycle. This would include post-translational
modifications of the viral proteins, such as glycosylation of the
spike and membrane proteins. Additionally, while the high through-
put screens described above for identifying inhibitors associated
with components of the viral entry system, such as ACE2, should
be confirmed in more translational assays, examples of which have
been described for HIV cell entry in an automatable format
(Bradley et al., 2004).
A desirable element would also be to minimize adverse effects on
the cardiovascular and respiratory systems, given the high incidence
of damage described associated with those systems (Esler &
Esler, 2020; Li, Yang, et al., 2020; Lippi, Lavie, & Sanchis-Gomar, 2020).
Candidate drugs should also not increase activity of the IL-6 (or any
other pro-inflammatory cytokine) pathway to avoid provoking a cyto-
kine storm.
If a similar approach were taken to the ways in which targeted
therapy is applied for certain types of cancer, there would be an
increased benefit in a multimodal strategy. Thus, in cancers where
EGF and EGF receptors are involved, it is possible to target the
ligand using chelating antibodies, to antagonize the receptor using
blocking antibodies, to use specific antibodies to prevent dimeriza-
tion of the receptor and to inhibit the catalytic activity of the recep-
tor with small molecular inhibitors. It should be possible to reproduce
this approach by simultaneously targeting several steps in the viral
cycle (while naturally being cognisant of the potential for phenomena
of drug:drug interactions, for instance, in terms of convergent path-
ways of drug metabolism). This approach, enacted for the treatment
of hepatitis C and human immunodeficiency viruses, for example,
should also show benefit in reducing the capacity for drug-driven
mutation in the enzyme.
From a DMPK perspective, a beneficial profile for any agent
would avoid drug:drug interactions by not converging on key
metabolic enzymes and/or transporters. Ideally, a once-daily treat-
ment regimen would be optimal, but if more frequent administra-
tion were needed, there is likely to be good patient adherence,
given the public response to 'spatial distancing'. From a formulation
perspective, prophylactic use or for treatment of mild symptoms,
an oral administered or inhaled formulation would be appropriate.
For more severe cases, where breathing is significantly impaired, an
inhaled aerosolized version maybe difficult to administer
effectively; in this circumstance, a soluble version to be applied
i.v. is likely to be useful.
Micro-organisms, such as viruses and bacteria, continue to evo-
lve to evade our immune systems and previous pandemics contrib-
uted to the decline and fall of civilizations. There is a widespread
hope that the current pandemic will be controlled by the rapid
development of a safe and efficacious vaccine. Clearly, there are
major successes with vaccines targeting viral disease, but, to date,
no vaccine has been successfully produced to protect against human
betacoronaviruses such as those causing SARS and MERS. On the
contrary, multiple viral diseases have been successfully controlled by
pharmacological agents. HIV-AIDS became more widespread in the
last century and was associated with high morbidity and mortality.
As a result of the discovery of novel pharmacological treatments,
including specific antivirals, it is now a chronic condition, and a cure
has been effected in at least two individuals. Similarly, the highly
variable hepatitis C virus has resisted vaccines but can be treated
with direct antiviral agents allowing elimination of the virus in a
very high proportion of those treated. This gives us hope that the
roadmap outlined in this review may provide some relief from
COVID-19 (and indeed for viral threats yet to come).
9.1 | Nomenclature of targets and ligands
Sequencing analysis of the novel virus has identified a high level of
similarity with the virus identified to cause the severe acute respira-
tory syndrome (SARS) outbreak in China in 2002/03/04, which was
known as the SARS coronavirus or SARS-CoV. Provisionally named as
2019-nCoV, the virus has been renamed SARS-CoV-2 (Coronaviridae
Study Group of the International Committee on Taxonomy of
Viruses, 2020). For the purposes of this document, the virus is
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described as SARS-CoV-2, while the infectious disease is named as
COVID-19 (World Health Organization, 2020). One of the positive
aspects of the emergence of SARS-CoV-2 and COVID-19 is the rapid-
ity at which aspects like genome sequencing (for example, Lu
et al., 2020; Wu et al., 2020) and 3D structures (for example, Yan
et al., 2020) have been described.
Protein targets and drugs in the current review follow nomencla-
ture as presented on the GuidetoPHARMACOLOGY.org website
(Alexander, Ball & Tsoleridis. SARS-CoV-2 proteins, accessed on
2020-04-24) and the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2019).
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